Ani Pharmaceuticals (ANIP) EBT Margin (2011 - 2026)

Ani Pharmaceuticals has disclosed EBT Margin across 16 years of filings, most recently posting 13.94% for Q2 2026.

• In Q2 2026, EBT Margin rose 896.0% year-over-year to 13.94%; the TTM figure through Jun 2026 stood at 14.57% (up 1655.0% YoY), while the FY2025 annual figure was 10.84%, up 1446.0% from the prior year.
• EBT Margin came in at 13.94% for Q2 2026 at Ani Pharmaceuticals, down from 16.94% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 18.43% in Q1 2024 to a low of 40.17% in Q1 2022.
• Average EBT Margin over 5 years is 0.47%, with a median of 3.28% recorded in 2023.
• The largest YoY upside for EBT Margin was 4456 bps in 2022 against a maximum downside of 4035 bps in 2022.
• Over 5 years, EBT Margin stood at 6.08% in 2022, then jumped by 112 bps to 0.72% in 2023, then slumped by 1104 bps to 7.22% in 2024, then surged by 276 bps to 12.74% in 2025, then rose by 9 bps to 13.94% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 13.94% in Q2 2026, 16.94% in Q1 2026, and 12.74% in Q4 2025.